March 11, 2024
Access & Coverage | Tea Leaves
  • More patients on insulin will pay less for the drug this year after a leading manufacturer joined rivals in curbing monthly costs or lowering prices. As of January 1, insulin maker Sanofi capped monthly out-of-pocket costs at $35 for its most popular product, Lantus, for patients with private insurance. Patients without insurance have already been able to get it at that cost. The drugmakers’ recent moves to curb insulin costs also represented a win for the Biden administration, which pressured companies to make the products more affordable after the Inflation Reduction Act capped monthly insulin costs at $35 in Medicare. (Articles here and here)